Almirall predicts positive 2021 development of psoriasis product

Dermatology company Almirall retreated in 2020 due to generic competition and Covid-19-related challenges, but the firm expects progress in 2021, aided by two of the firm's newest products.

Photo: Mikkel Aabenhus Hemmingsen / MedWatch

In early 2020, already, Almirall warned this wouldn't be the best year. Competition from US generic products would have a severe impact, and the firm was facing a series of investments.

The Covid-19 crisis piled on top of this situation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Latest news

See all jobs